Israel - hebreu - Ministry of Health

novartis pharma services ag - glyceryl trinitrate 50 mg/patch - patches - glyceryl trinitrate - prophylaxis of angina pectoris.

Israel - hebreu - Ministry of Health

novartis pharma services ag - amlodipine as besylate 5 mg; valsartan 320 mg - film coated tablets - valsartan - exforge ( amlodipine and valsartan) is insicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension.

Israel - hebreu - Ministry of Health

novartis pharma services ag - amlodipine as besylate 10 mg; valsartan 320 mg - film coated tablets - valsartan - exforge ( amlodipine and valsartan) is insicated for the treatment of hypertension. this fixed combination drug is not indicated for the initial therapy of hypertension.

Israel - hebreu - Ministry of Health

novartis pharma services ag - telbivudine 600 mg - film coated tablets - telbivudine - treatment of chronic hepatitis b in patients with evidence of viral replication and active liver inflammation in adults over 16 years of age.the following points should be considered when initiating therapy with sebivo:- for hbeag - positive patients, sebivo treatment should only be initiated in patients with baseline hbv dna < 9log 10 copies/ml and baseline alt>or= 2x uln.- for hbeag - negative patients, sebivo treatment should only be initiated in patients with baseline hbv dna < 7log 10 copies/ml.

Israel - hebreu - Ministry of Health

novartis pharma services ag - verteporfin 15 mg/vial - solution for infusion - verteporfin - visudyne is indicated for the treatment of patients with predominantly classic or occult subfoveal choroidal neovascularization due to age related macular degeneration, or with subfoveal choroidal neovascularization caused by other macular diseases.

Israel - hebreu - Ministry of Health

novartis pharma services ag - imatinib as mesylate 100 mg - capsules - imatinib - treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ - cml) in chronic phase, accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist).

Israel - hebreu - Ministry of Health

novartis pharma services ag - imatinib as mesylate 100 mg - film coated tablets - imatinib - glivec is indicated for the treatment of adult patients and children 3 years of age and above with ph+ chronic myeloid leukaemia (ph+ -cml) in chronic phase accelerated phase or blast crisis. glivec is also indicated for the treatment of adult patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). glivec is also indicated for the treament of : adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph + all as monotherapy. adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. adult patients with myelodyspiastic/myeloproliferative diseases (mds/mpd) associated with pdgfr ( platelet - derived growth factor receptor ) gene re- arrangements. adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic l

Israel - hebreu - Ministry of Health

novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm

Israel - hebreu - Ministry of Health

novartis pharma services ag - mycophenolic acid 180 mg - film coated tablets - mycophenolic acid - myfortic is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.

Israel - hebreu - Ministry of Health

novartis pharma services ag - mycophenolic acid 360 mg - film coated tablets - mycophenolic acid - myfortic is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants.